Ongoing Investigation by Pomerantz Law Firm for Sanofi Investors Amid Fraud Claims
On June 22, 2025, Pomerantz LLP announced an investigation on behalf of investors who have stakes in Sanofi, a prominent pharmaceutical company traded under NASDAQ symbol SNY. The law firm has encouraged investors who might have experienced losses to reach out, as there are concerns relating to possible securities fraud and illegal business practices conducted by Sanofi's officers or directors.
The trigger for this investigation was Sanofi's troubling announcement made on May 30, 2025, regarding mixed results from a major clinical trial for itepekimab, an antibody treatment for chronic obstructive pulmonary disease (COPD). While the AERIFY-1 trial succeeded in meeting its primary endpoint with promising results, the AERIFY-2 trial was unable to replicate these favorable outcomes. Following this disheartening news, Sanofi’s American Depositary Receipt (ADR) plummeted by $2.98, marking a significant decline of 5.69% to close at $49.37.
Pomerantz LLP has a distinguished track record in corporate and securities litigation and is recognized nationally for its dedication to defending the rights of investors. With offices across major cities such as New York, Chicago, Los Angeles, London, and Paris, the firm has built a strong reputation since its founding over 80 years ago. It was established by Abraham L. Pomerantz, who is often credited as the pioneer of class action lawsuits. His legacy continues as the firm strives to safeguard the interests of victims affected by securities fraud, breaches of fiduciary duty, and other corporate wrongdoings.
As the investigation unfolds, affected Sanofi investors have the opportunity to participate in class-action lawsuits aimed at recovering their losses. Interested parties are advised to contact Danielle Peyton at Pomerantz LLP for further guidance on how to proceed. The firm’s commitment to securing justice for its clients remains unwavering, and they have successfully recovered multi-million dollar settlements on behalf of numerous class members in the past.
In light of these developments, investors are reminded to stay vigilant regarding their investments and to consult with legal professionals when uncertain about their rights and options in the face of corporate litigation. The implications of this investigation could be significant for both Sanofi and its investors, as potential misconduct comes to light.
For further information about the ongoing investigation and details on getting involved, impacted investors are encouraged to visit the firm’s official website, where they can find more resources related to securities litigation and investor rights. This investigation serves as a timely reminder of the importance of ethical corporate governance and transparency in the pharmaceutical industry, especially as it affects the health and welfare of consumers who rely on effective treatments and medications.
The trigger for this investigation was Sanofi's troubling announcement made on May 30, 2025, regarding mixed results from a major clinical trial for itepekimab, an antibody treatment for chronic obstructive pulmonary disease (COPD). While the AERIFY-1 trial succeeded in meeting its primary endpoint with promising results, the AERIFY-2 trial was unable to replicate these favorable outcomes. Following this disheartening news, Sanofi’s American Depositary Receipt (ADR) plummeted by $2.98, marking a significant decline of 5.69% to close at $49.37.
Pomerantz LLP has a distinguished track record in corporate and securities litigation and is recognized nationally for its dedication to defending the rights of investors. With offices across major cities such as New York, Chicago, Los Angeles, London, and Paris, the firm has built a strong reputation since its founding over 80 years ago. It was established by Abraham L. Pomerantz, who is often credited as the pioneer of class action lawsuits. His legacy continues as the firm strives to safeguard the interests of victims affected by securities fraud, breaches of fiduciary duty, and other corporate wrongdoings.
As the investigation unfolds, affected Sanofi investors have the opportunity to participate in class-action lawsuits aimed at recovering their losses. Interested parties are advised to contact Danielle Peyton at Pomerantz LLP for further guidance on how to proceed. The firm’s commitment to securing justice for its clients remains unwavering, and they have successfully recovered multi-million dollar settlements on behalf of numerous class members in the past.
In light of these developments, investors are reminded to stay vigilant regarding their investments and to consult with legal professionals when uncertain about their rights and options in the face of corporate litigation. The implications of this investigation could be significant for both Sanofi and its investors, as potential misconduct comes to light.
For further information about the ongoing investigation and details on getting involved, impacted investors are encouraged to visit the firm’s official website, where they can find more resources related to securities litigation and investor rights. This investigation serves as a timely reminder of the importance of ethical corporate governance and transparency in the pharmaceutical industry, especially as it affects the health and welfare of consumers who rely on effective treatments and medications.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.